Striving towards disease-free skin
Written by Ali Azimi Recently, our original research paper titled “In Silico Analysis Validates Proteomic Findings of Formalin-fixed Paraffin Embedded Cutaneous Squamous Cell Carcinoma Tissue” has been accepted for publication in the journal of Cancer Genomics & Proteomics (CGP). The manuscript will be published in the next available issue of CGP. CGP is an international …
The JAAD has recently published our paper describing the cutaneous immune-related adverse events (irAE) that appear with anti-PD1 monoclonal antibodies (pembrolizumab or nivolumab). These molecules do not create the dramatic changes in melanoma metastasis that BRAF inhibitors show, but it seems to create more sustained responses. Moreover, they are the most effective treatment for patients …
This is another area of interest in our group: the cutaneous manifestations of acute and chronic Graft versus Host Disease. We have a monthly multidisciplinary clinic with Haematology in the Crown Princess Mary Cancer Centre at Westmead Hospital. The Haematology group is developing a fantastic team of specialists (Respiratory, Endocrinology, Gynaecology, etc) around their clinic. …
The impact of skin conditions in the quality of life of dermatology patients is usually unappreciated by many physicians, and it is one of our areas of interest. We have several projects evaluating different instruments and assessments. At the Skin and Cancer Foundation Australia a group of very keen medical students are working with our …
We have a new paper on the cutaneous adverse events of BRAF inhibitor based therapies in patients with metastatic malignant melanoma. It is fantastic that patients are surviving more than 1 year with these therapies, but dermatologists and oncologists should be aware that side effects from these medications are still present and need to be …